Related Experiment Video
Updated: Jun 22, 2025
09:57
Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues
Published on: October 17, 2022
2.0K
Active antithrombin glycoforms are selectively physiosorbed on plasma extracellular vesicles.
Annalisa Radeghieri1,2, Silvia Alacqua1, Andrea Zendrini1,2
1Department of Molecular and Translational Medicine University of Brescia Brescia Italy.
Journal of Extracellular Biology
|June 28, 2024
Summary
Active antithrombin (AT) binds to extracellular vesicles (EVs), forming a protein corona. Differences in AT glycoforms on EVs may help diagnose AT qualitative deficiency.
Area of Science:
- Biochemistry
- Hematology
- Nanomedicine
Background:
- Antithrombin (AT) is a key inhibitor of blood clotting proteases.
- AT qualitative deficiency is difficult to diagnose using current methods.
Purpose of the Study:
- To investigate the interaction of active antithrombin (AT) with plasma extracellular vesicles (EVs).
- To explore the role of AT glycosylation in its association with EVs.
- To determine if EV-bound AT glycoforms can serve as biomarkers for AT qualitative deficiency.
Main Methods:
- Isolation and characterization of plasma extracellular vesicles (EVs).
- Analysis of the protein corona composition, focusing on antithrombin (AT) glycoforms.
- Comparison of EV-protein corona from healthy individuals and patients with AT qualitative deficiency.
Main Results:
- Active AT was found physiosorbed on the surface of plasma EVs, contributing to the EV-protein corona.
- The EV-protein corona showed enrichment in specific AT glycoforms, indicating a role for glycosylation.
- Distinct differences in AT glycoform composition were observed between healthy subjects and those with AT qualitative deficiency.
Conclusions:
- Extracellular vesicles (EVs) carry active antithrombin (AT) in the plasma.
- EV-associated AT glycoforms may offer novel diagnostic insights into AT qualitative deficiency.
- Analyzing nanostructured plasma components like EVs could reveal new pathophysiological mechanisms.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:16Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
01:29Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
01:21Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K